The Ethical Problems of the Open Label Extension Study

Cambridge Quarterly of Healthcare Ethics 5 (3):410 (1996)
  Copy   BIBTEX

Abstract

The institutional review board Is charged with assessing the risks and benefits of research projects Involving human subjects. Ethical considerations and federal regulations require that an IRB, in part, must find that the potential risks of participation are proportional to the potential benefits and to the Importance of the knowledge that may be learned before the IRB can approve the voluntary assumption of risk by a research participant. Adequate assessment of the risks and benefits requires careful scrutiny of the study design In relation to the study objectives

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 103,567

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

The Ethical Analysis of Risk.Charles Weijer - 2000 - Journal of Law, Medicine and Ethics 28 (4):344-361.
The Merits of Procedure-Level Risk-Benefit Assessment.Anna Westra & Inez de Beaufort - 2011 - IRB: Ethics & Human Research 33 (5):7-13.
A framework for risk-benefit evaluations in biomedical research.Annette Rid & David Wendler - 2011 - Kennedy Institute of Ethics Journal 21 (2):141-179.

Analytics

Added to PP
2010-08-24

Downloads
57 (#399,161)

6 months
7 (#519,682)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Open-Label Extension Studies: Are They Really Research?Mildred K. Cho - 2014 - American Journal of Bioethics 14 (3):1-2.
Post-trial access to treatment: corporate best practices.Irene Schipper & Silvia Colona - 2015 - SOMO Centre for Research on Multinational Corporations.
Open-Label Extension Studies: Are They Really Research?Mildred K. Cho - 2014 - American Journal of Bioethics 14 (4):60-61.

Add more citations